RT Journal Article
SR Electronic
T1 Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.25.20201863
DO 10.1101/2020.09.25.20201863
A1 Vella, Laura A.
A1 Giles, Josephine R.
A1 Baxter, Amy E.
A1 Oldridge, Derek A.
A1 Diorio, Caroline
A1 Kuri-Cervantes, Leticia
A1 Alanio, Cécile
A1 Pampena, M. Betina
A1 Wu, Jennifer E.
A1 Chen, Zeyu
A1 Huang, Yinghui Jane
A1 Anderson, Elizabeth M.
A1 Gouma, Sigrid
A1 McNerney, Kevin O.
A1 Chase, Julie
A1 Burudpakdee, Chakkapong
A1 Lee, Jessica H.
A1 Apostolidis, Sokratis A.
A1 Huang, Alexander C.
A1 Mathew, Divij
A1 Kuthuru, Oliva
A1 Goodwin, Eileen C.
A1 Weirick, Madison E.
A1 Bolton, Marcus J.
A1 Arevalo, Claudia P.
A1 Ramos, Andre
A1 Jasen, Cristina
A1 Giannini, Heather M.
A1 D’Andrea, Kurt
A1 ,
A1 Meyer, Nuala J.
A1 Behrens, Edward M.
A1 Bassiri, Hamid
A1 Hensley, Scott E.
A1 Henrickson, Sarah E.
A1 Teachey, David T.
A1 Betts, Michael R.
A1 Wherry, E. John
YR 2020
UL http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201863.abstract
AB Pediatric COVID-19 following SARS-CoV-2 infection is associated with fewer hospitalizations and often milder disease than in adults. A subset of children, however, present with Multisystem Inflammatory Syndrome in Children (MIS-C) that can lead to vascular complications and shock, but rarely death. The immune features of MIS-C compared to pediatric COVID-19 or adult disease remain poorly understood. We analyzed peripheral blood immune responses in hospitalized SARS-CoV-2 infected pediatric patients (pediatric COVID-19) and patients with MIS-C. MIS-C patients had patterns of T cell-biased lymphopenia and T cell activation similar to severely ill adults, and all patients with MIS-C had SARS-CoV-2 spike-specific antibodies at admission. A distinct feature of MIS-C patients was robust activation of vascular patrolling CX3CR1+ CD8 T cells that correlated with use of vasoactive medication. Finally, whereas pediatric COVID-19 patients with acute respiratory distress syndrome (ARDS) had sustained immune activation, MIS-C patients displayed clinical improvement over time, concomitant with decreasing immune activation. Thus, non-MIS-C versus MIS-C SARS-CoV-2 associated illnesses are characterized by divergent immune signatures that are temporally distinct and implicate CD8 T cells in clinical presentation and trajectory of MIS-C.One Sentence Summary MIS-C is defined by generalized lymphocyte activation that corrects during hospitalization, including elevated plasmablast frequencies and marked activation of vascular patrolling CX3CR1+ CD8 T cells.Competing Interest StatementScEH has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. EJW has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. EJW is a founder of Surface Oncology and Arsenal Biosciences. EJW has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. EJW is an inventor on a patent (US Patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer.Funding StatementLAV is funded by a Mentored Clinical Scientist Career Development Award from NIAID (K08 AI136660). This work was supported by the University of Pennsylvania Institute for Immunology Glick COVID19 research award (MRB), NIH AI105343, AI08263, and the Allen Institute for Immunology (EJW). The adult COVID19 cohort was supported by NIH HL137006 and HL137915 (NJM) and the UPenn Institute for Immunology. ACH was funded by grant CA230157 from the NIH. DM and JG were supported by T32 CA009140 and EMA was supported by T32AI007324. ZC was funded by NIH grant CA234842. DAO was funded by NHLBI R38 HL143613 and NCI T32 CA009140. NJM reports funding to her institution from Athersys, Inc., Biomarck, Inc., and the Marcus Foundation for Research. JRG is a Cancer Research Institute-Mark Foundation Fellow. JRG, JEW, CA, and EJW are supported by the Parker Institute for Cancer Immunotherapy which supports the Cancer Immunology program at the University of Pennsylvania. Support was also provided by the CHOP Frontiers Program Immune Dysregulation Team (DTT, EB, HB), NIAID R01AI121250 (EMB), NCI R01CA193776 (DTT), Leukemia and Lymphoma Society (DTT), Alexs Lemonade Stand Foundation for Childhood Cancer (DTT). We thank Jeffrey Lurie and we thank Joel Embiid, Josh Harris, David Blitzer for philanthropic support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Boards of the University of Pennsylvania and Children's Hospital of PhiladelphiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.